Oppenheimer downgraded enGene (ENGN) to Perform from Outperform. The firm views updated interim data from the pivotal LEGEND cohort in BCG-unresponsive NMIBC as disappointing, and while the approval door may remain open, Oppenheimer is less optimistic on detalimogene’s ability to compete in this evolving marketplace. The firm believes that enGene is now a “show-me” story for which investor enthusiasm will be limited for the foreseeable future. Oppenheimer expects an update on BLA submission plans in the second half of 2026 following the company’s further engagement with FDA.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene downgraded to Market Perform from Outperform at Leerink
- Leland Gershell Reiterates Hold on enGene as LEGEND Trial Efficacy Declines and Withdraws Sales Forecasts and Price Target Pending Greater Clarity
- enGene downgraded to Outperform from Strong Buy at Raymond James
- enGene downgraded to Neutral from Buy at Guggenheim
- enGene downgraded to Neutral from Overweight at Piper Sandler